Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
Eton Pharmaceuticals (certain assets)
Slayback Pharma |
| gptkbp:CEO |
gptkb:Richard_Blackburn
|
| gptkbp:focusesOn |
rare diseases
specialty medicines liquid medications |
| gptkbp:formerName |
CutisPharma
|
| gptkbp:foundedYear |
1998
|
| gptkbp:headquartersLocation |
gptkb:Wilmington,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Azurity Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:openToPublic |
private
|
| gptkbp:product |
gptkb:Tuzistra_XR
gptkb:Epaned gptkb:Zenzedi FIRVANQ Katerzia Trecator Xatmep |
| gptkbp:website |
https://www.azurity.com/
|
| gptkbp:bfsParent |
gptkb:Prexxartan
|
| gptkbp:bfsLayer |
7
|